-
1
-
-
0642371188
-
Anidulafungin: ECB, LY 303366, V-echinocandin, VEC, VER 002, VER-02
-
Anidulafungin: ECB, LY 303366, V-echinocandin, VEC, VER 002, VER-02. Drugs ,R&D (2003) 4:167-173.
-
(2003)
Drugs R&D
, vol.4
, pp. 167-173
-
-
-
2
-
-
0142214407
-
Anidulafungin
-
MARTIN-MAZUELOS E: Anidulafungin. IDrugs (2003) 6:980-986.
-
(2003)
IDrugs
, vol.6
, pp. 980-986
-
-
Martin-Mazuelos, E.1
-
3
-
-
0030779919
-
Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans
-
KRISHNARAO TV, GALGIANI JN: Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. (1997) 41:1957-1960.
-
(1997)
Antimicrob. Agents Chemother.
, vol.41
, pp. 1957-1960
-
-
Krishnarao, T.V.1
Galgiani, J.N.2
-
4
-
-
0030896919
-
In vitro activity of a new semisynthetic echinocandin, LY303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species
-
ZHANEL GG, KARLOWSKY JA, HARDING GA et al.: In vitro activity of a new semisynthetic echinocandin, LY303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob. Agents Chemother. (1997) 41:863-865.
-
(1997)
Antimicrob. Agents Chemother.
, vol.41
, pp. 863-865
-
-
Zhanel, G.G.1
Karlowsky, J.A.2
Harding, G.A.3
-
5
-
-
0035147071
-
Update on antifungals targeted to the cell wall: Focus on β-1, 3-glucan synthase inhibitors
-
GEORGOPARADAKOU NH: Update on antifungals targeted to the cell wall: focus on β-1, 3-glucan synthase inhibitors. Expert Opin. Investig. Drugs (2001) 10:269-280.
-
(2001)
Expert Opin. Investig. Drugs
, vol.10
, pp. 269-280
-
-
Georgoparadakou, N.H.1
-
6
-
-
0030943354
-
Lipopeptide inhibitors of fungal glucan synthase
-
KURTZ MB, DOUGLAS CM: Lipopeptide inhibitors of fungal glucan synthase. J. Med. Vet. Mycol. (1997) 35:79-86.
-
(1997)
J. Med. Vet. Mycol.
, vol.35
, pp. 79-86
-
-
Kurtz, M.B.1
Douglas, C.M.2
-
7
-
-
0038107441
-
Caspofungin: First approved agent in a new class of antifungals
-
JOHNSON MD, PERFECT JR. Caspofungin: first approved agent in a new class of antifungals. Expert Opin. Pharmacother. (2003) 4:807-823.
-
(2003)
Expert Opin. Pharmacother.
, vol.4
, pp. 807-823
-
-
Johnson, M.D.1
Perfect, J.R.2
-
8
-
-
0035215090
-
Clinical efficacy of echinocandin antifungals
-
ARATHOON EG: Clinical efficacy of echinocandin antifungals. Curr. Opin. Infect. Dis. (2001) 14:685-691.
-
(2001)
Curr. Opin. Infect. Dis.
, vol.14
, pp. 685-691
-
-
Arathoon, E.G.1
-
9
-
-
2442671132
-
Anidulafungin biotransformation in humans is by degradation not metabolism
-
STOGNIEW M, PU F, HENKEL T, DOWELL J: Anidulafungin biotransformation in humans is by degradation not metabolism. Clin. Microbiol. Infect. (2003) 9:91.
-
(2003)
Clin. Microbiol. Infect.
, vol.9
, pp. 91
-
-
Stogniew, M.1
Pu, F.2
Henkel, T.3
Dowell, J.4
-
10
-
-
2442695447
-
Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal
-
DOWELL JA, KNEBEL W, LUDDEN T, STOGNIEW M, KRAUSE D, HENKEL T: Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J. Clin. Pharm. (2004) 44:590-598.
-
(2004)
J. Clin. Pharm.
, vol.44
, pp. 590-598
-
-
Dowell, J.A.1
Knebel, W.2
Ludden, T.3
Stogniew, M.4
Krause, D.5
Henkel, T.6
-
12
-
-
0035198908
-
The echinocandins, first novel class of antifungals in two decades: Will they live up their promise?
-
GRAYBILL JR: The echinocandins, first novel class of antifungals in two decades: Will they live up their promise? Int. J. Clin. Pract. (2001) 55:633-638.
-
(2001)
Int. J. Clin. Pract.
, vol.55
, pp. 633-638
-
-
Graybill, J.R.1
-
13
-
-
0030671386
-
Identification of the FKS1 gene of Candida albicans as the essential target of 1, 3-β-D-glucan synthase inhibitors
-
DOUGLAS CM, D'IPPOLITO JA, SHEI GJ et al.: Identification of the FKS1 gene of Candida albicans as the essential target of 1, 3-β-D-glucan synthase inhibitors: Antimicrob. Agents Chemother. (1997) 41:2471-2479.
-
(1997)
Antimicrob. Agents Chemother.
, vol.41
, pp. 2471-2479
-
-
Douglas, C.M.1
D'Ippolito, J.A.2
Shei, G.J.3
-
14
-
-
0028004384
-
Antibiotics that inhibit fungal cell wall development
-
DEBONO M, GORDEE RS: Antibiotics that inhibit fungal cell wall development. Ann. Rev. Microbiol. (1994) 48:471-497.
-
(1994)
Ann. Rev. Microbiol.
, vol.48
, pp. 471-497
-
-
Debono, M.1
Gordee, R.S.2
-
15
-
-
0027439619
-
Compounds active against cell walls of medically important fungi
-
HECTOR RF: Compounds active against cell walls of medically important fungi. Clin. Microbiol. Rev. (1993) 6:1-21.
-
(1993)
Clin. Microbiol. Rev.
, vol.6
, pp. 1-21
-
-
Hector, R.F.1
-
16
-
-
12244253742
-
Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: A comparative study with M27-A microdilution method
-
AREVALO MP, CARRILLO-MUNOZ A-J, SALGADO J et al.: Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J. Antimicrob. Chemother. (2003) 51:163-166.
-
(2003)
J. Antimicrob. Chemother.
, vol.51
, pp. 163-166
-
-
Arevalo, M.P.1
Carrillo-Munoz, A.-J.2
Salgado, J.3
-
17
-
-
0031689491
-
Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
-
ESPINEL-INGROFF A: Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. (1998) 36:2950-2956.
-
(1998)
J. Clin. Microbiol.
, vol.36
, pp. 2950-2956
-
-
Espinel-Ingroff, A.1
-
18
-
-
0032422450
-
Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp
-
MARCO F, PFALLER MA, MESSER SA, JONES RN: Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn, Microbiol. Infect. Dis. (1998) 31:33-37.
-
(1998)
Diagn. Microbiol. Infect. Dis.
, vol.31
, pp. 33-37
-
-
Marco, F.1
Pfaller, M.A.2
Messer, S.A.3
Jones, R.N.4
-
19
-
-
0030970811
-
In vitro activity of a new echinocandin, LY-303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates
-
UZUN O, KOCAGOZ S, CETINKAYA Y, ARIKAN S, UNAL S: In vitro activity of a new echinocandin, LY-303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob. Agents Chemother. (1997) 41:1156-1157.
-
(1997)
Antimicrob. Agents Chemother.
, vol.41
, pp. 1156-1157
-
-
Uzun, O.1
Kocagoz, S.2
Cetinkaya, Y.3
Arikan, S.4
Unal, S.5
-
20
-
-
0031943562
-
In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743, 792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi
-
PFALLER MA, MARCO F, MESSER SA, JONES RN: In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743, 792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. (1998) 30:251-255.
-
(1998)
Diagn. Microbiol. Infect. Dis.
, vol.30
, pp. 251-255
-
-
Pfaller, M.A.1
Marco, F.2
Messer, S.A.3
Jones, R.N.4
-
21
-
-
0031977161
-
Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a routine model of invasive aspergillosis
-
VERWEIJ PE, OAKLEY KL, MORRISSEY J, MORRISSEY G, DENNING DW: Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a routine model of invasive aspergillosis. Antimicrob. Agents Chemother. (1998) 42:873-878.
-
(1998)
Antimicrob. Agents Chemother.
, vol.42
, pp. 873-878
-
-
Verweij, P.E.1
Oakley, K.L.2
Morrissey, J.3
Morrissey, G.4
Denning, D.W.5
-
22
-
-
2142707210
-
In vitro activity of anidulafungin against selected clinically important mold isolates
-
ODABASI Z, PAETZNICK VL, RODRIQUEZ JR, CHEN E, OSTROSKY-ZEICHNER L: In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob. Agents Chemother. (2004) 48:1912-1915.
-
(2004)
Antimicrob. Agents Chemother.
, vol.48
, pp. 1912-1915
-
-
Odabasi, Z.1
Paetznick, V.L.2
Rodriquez, J.R.3
Chen, E.4
Ostrosky-Zeichner, L.5
-
23
-
-
0029837527
-
Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo
-
BARTLETT MS, CURRENT WL, GOHEEN MP et al.: Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo. Antimicrob. Agents Chemother. (1996) 40:1811-1816.
-
(1996)
Antimicrob. Agents Chemother.
, vol.40
, pp. 1811-1816
-
-
Bartlett, M.S.1
Current, W.L.2
Goheen, M.P.3
-
25
-
-
0033680483
-
The effects of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans
-
FELDMESSER M, KRESS Y, MEDNICK A, CASADEVALL A: The effects of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J. Infect. Dis. (2000) 182:1791-1795.
-
(2000)
J. Infect. Dis.
, vol.182
, pp. 1791-1795
-
-
Feldmesser, M.1
Kress, Y.2
Mednick, A.3
Casadevall, A.4
-
26
-
-
0030055323
-
Characterization of echinocandin-resistant mutants of Candida albicans: Genetic, biochemical, and virulence studies
-
KURTZ MB, ABRUZZO G, FLATTERY A et al.: Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect. Immun. (1996) 64:3244-3251.
-
(1996)
Infect. Immun.
, vol.64
, pp. 3244-3251
-
-
Kurtz, M.B.1
Abruzzo, G.2
Flattery, A.3
-
27
-
-
0035991843
-
Overespression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccaromyces cerevisiase
-
OSHEROV N, MAY GS, ALBERT ND, KONTOYIANNIS DP: Overespression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccaromyces cerevisiase. Antilmicrob. Agents Chemother. (2002) 46:2462-2469.
-
(2002)
Antilmicrob. Agents Chemother.
, vol.46
, pp. 2462-2469
-
-
Osherov, N.1
May, G.S.2
Albert, N.D.3
Kontoyiannis, D.P.4
-
28
-
-
0037137576
-
Comparison of caspofungin and amphotericin B for invasive candidiasis
-
MORA-DUARTE J, BETTS R, ROTSTEIN C et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. (2002) 347:2020-2029.
-
(2002)
N. Engl. J. Med.
, vol.347
, pp. 2020-2029
-
-
Mora-Duarte, J.1
Betts, R.2
Rotstein, C.3
-
29
-
-
2542434169
-
Phase II, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia
-
KRAUSE DS, REINHARDT J, VAZQUEZ JA et al.: Phase II, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother. (2004) 48:2021-2024.
-
(2004)
Antimicrob. Agents Chemother.
, vol.48
, pp. 2021-2024
-
-
Krause, D.S.1
Reinhardt, J.2
Vazquez, J.A.3
-
30
-
-
4544382225
-
A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis
-
(In press)
-
KRAUSE DS, SIMJEE AE, VAN RENSBURG C et al.: A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. (2004) (In press).
-
(2004)
Clin. Infect. Dis.
-
-
Krause, D.S.1
Simjee, A.E.2
Van Rensburg, C.3
-
31
-
-
0036701952
-
A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis
-
VILLANUEVA A, GOTUZZO E, ARATHOON A et al.: A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. (2002) 113:294-299.
-
(2002)
Am. J. Med.
, vol.113
, pp. 294-299
-
-
Villanueva, A.1
Gotuzzo, E.2
Arathoon, A.3
-
32
-
-
0028017480
-
The natural history of esophageal candidiasis after successful treatment in patients with AIDS
-
LAINE L: The natural history of esophageal candidiasis after successful treatment in patients with AIDS. Gastroenterology (1994) 107:744-746.
-
(1994)
Gastroenterology
, vol.107
, pp. 744-746
-
-
Laine, L.1
-
33
-
-
0037108380
-
Has antifungal susceptibility testing come of age?
-
REX JH, PFALLER MA: Has antifungal susceptibility testing come of age? Clin. Infect. Dis. (2002) 35:982-989.
-
(2002)
Clin. Infect. Dis.
, vol.35
, pp. 982-989
-
-
Rex, J.H.1
Pfaller, M.A.2
-
34
-
-
0031833836
-
Evaluation of endpoints for antifungal susceptibility determinations with LY303366
-
KLEPSER ME, ERNST EJ, ERNST ME, MESSER SA, PFALLER MA: Evaluation of endpoints for antifungal susceptibility determinations with LY303366. Antimicrob. Agents Cbemother. (1998) 42:1387-1391.
-
(1998)
Antimicrob. Agents Cbemother.
, vol.42
, pp. 1387-1391
-
-
Klepser, M.E.1
Ernst, E.J.2
Ernst, M.E.3
Messer, S.A.4
Pfaller, M.A.5
-
35
-
-
1642420267
-
Caspofungin resistance in Candida albicans: Correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis
-
HERNANDEZ S, LOPEZ-RIBOT JL, NAJVAR LK, McCARTHY DI, BOCANEGRA R, GRAYBILL JR: Caspofungin resistance in Candida albicans. correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother. (2004) 48:1382-1383.
-
(2004)
Antimicrob. Agents Chemother.
, vol.48
, pp. 1382-1383
-
-
Hernandez, S.1
Lopez-Ribot, J.L.2
Najvar, L.K.3
McCarthy, D.I.4
Bocanegra, R.5
Graybill, J.R.6
-
36
-
-
0034812542
-
Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): Reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling
-
GROLL AH, MICKIENE D, PETRAITIENE R et al.: Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob. Agents Chemother. (2001) 45:2845-2855.
-
(2001)
Antimicrob. Agents Chemother.
, vol.45
, pp. 2845-2855
-
-
Groll, A.H.1
Mickiene, D.2
Petraitiene, R.3
-
38
-
-
0005966101
-
Anidulafungin: A Phase I study to identify the maximum tolerated dose in healthy volunteers
-
Chicago, USA Abstract 36
-
THYE D, SHEPHERD B, WHITE RJ, WESTON IE, HENKEL T: Anidulafungin: a Phase I study to identify the maximum tolerated dose in healthy volunteers. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA (2001) Abstract 36.
-
(2001)
Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Thye, D.1
Shepherd, B.2
White, R.J.3
Weston, I.E.4
Henkel, T.5
-
39
-
-
6044220026
-
A clinical mass balance study of anidulafungin showing complete fecal elimination
-
Chicago, USA Abstract A1576
-
DOWELL JA, PU F, LEE J, STOGNIEW M, KRAUSE D, HENKEL T: A clinical mass balance study of anidulafungin showing complete fecal elimination. Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA (2003) Abstract A1576.
-
(2003)
Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Dowell, J.A.1
Pu, F.2
Lee, J.3
Stogniew, M.4
Krause, D.5
Henkel, T.6
-
40
-
-
0142254305
-
Anidulafungin dosage adjustments are not required for patients with hepatic and/or renal impairment
-
DOWELL J, STOGNIEW M, KRAUSE D: Anidulafungin dosage adjustments are not required for patients with hepatic and/or renal impairment. Clin. Microbiol. Infect. (2003) 9:1222.
-
(2003)
Clin. Microbiol. Infect.
, vol.9
, pp. 1222
-
-
Dowell, J.1
Stogniew, M.2
Krause, D.3
-
43
-
-
0038436812
-
Anidulafungin: Pharmacokinetics in subjects receiving hemodialysis
-
Chicago, USA Abstract A1390
-
THYE D, MARBUY T, KILFOIL T, KILFOIL G, HENKEL T: Anidulafungin: pharmacokinetics in subjects receiving hemodialysis. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA (2001) Abstract A1390.
-
(2001)
Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Thye, D.1
Marbuy, T.2
Kilfoil, T.3
Kilfoil, G.4
Henkel, T.5
-
44
-
-
0038436812
-
Anidulafungin: Pharmacokinetics in subjects with renal impairment
-
Chicago, USA Abstract A1391
-
THYE D, MARBUY T, KILFOIL G, KILFOIL G, HENKEL T: Anidulafungin: pharmacokinetics in subjects with renal impairment. Abstracts ofthe 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA (2001) Abstract A1391.
-
(2001)
Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Thye, D.1
Marbuy, T.2
Kilfoil, G.3
Kilfoil, G.4
Henkel, T.5
-
46
-
-
0033977727
-
Toxicity of LY303366, an echinocandin antifungal in mice pretreated with glucocorticoids
-
CLEMONS K, SOBEL RA, STEVENS DA: Toxicity of LY303366, an echinocandin antifungal in mice pretreated with glucocorticoids. Antimicrob. Agents Chemother. (2000) 44:378-381.
-
(2000)
Antimicrob. Agents Chemother.
, vol.44
, pp. 378-381
-
-
Clemons, K.1
Sobel, R.A.2
Stevens, D.A.3
-
47
-
-
4544296621
-
Anidulafungin, a novel antifungal agent, produces no overt toxicity when administered to DBA/2 and BALB/c mice, with or without cortisone acetate. Vicuron
-
(Data on file)
-
STOGNIEW M, SENG JE, HOBERMAN A, HENKEL T: Anidulafungin, a novel antifungal agent, produces no overt toxicity when administered to DBA/2 and BALB/c mice, with or without cortisone acetate. Vicuron (Data on file).
-
-
-
Stogniew, M.1
Seng, J.E.2
Hoberman, A.3
Henkel, T.4
-
48
-
-
0030295028
-
Antifungal dynamics of LY303366, an investigational echinocandin B analog, against Candida spp
-
ERNST ME, KLEPSER ME, WOLFE EJ, PFALLER MA: Antifungal dynamics of LY303366, an investigational echinocandin B analog, against Candida spp. Diagn. Microbiol. Infect. Dis. (1996) 26:125-131.
-
(1996)
Diagn. Microbiol. Infect. Dis.
, vol.26
, pp. 125-131
-
-
Ernst, M.E.1
Klepser, M.E.2
Wolfe, E.J.3
Pfaller, M.A.4
-
49
-
-
0030685788
-
In vitro kill curves of a new semisynthetic echinocandin LY303366, against fluconazole sensitive and resistant Candida species
-
KARLOWSKY JA, HARDING GA, ZELENITSKY SA et al.: In vitro kill curves of a new semisynthetic echinocandin LY303366, against fluconazole sensitive and resistant Candida species. Antimicrob. Agents Chemother. (1997) 41:2576-2578.
-
(1997)
Antimicrob. Agents Chemother.
, vol.41
, pp. 2576-2578
-
-
Karlowsky, J.A.1
Harding, G.A.2
Zelenitsky, S.A.3
-
50
-
-
2042454166
-
Determination of fungicidal activities against yeasts and molds: Lessons learned from bactericidal testing and the need for standardization
-
PFALLER MA, SHEEHAN DJ, REX JH: Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin. Microbiol. Rev. (2004) 17:268-280.
-
(2004)
Clin. Microbiol. Rev.
, vol.17
, pp. 268-280
-
-
Pfaller, M.A.1
Sheehan, D.J.2
Rex, J.H.3
-
51
-
-
0036272920
-
Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY303366) alone and in combination against Candida spp. and Cryptococcus neoformans via time-kill methods
-
ROLING EE, KLEPSER ME, WASSON A, LEWIS RE, ERNST EJ, PFALLER MA: Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY303366) alone and in combination against Candida spp. and Cryptococcus neoformans via time-kill methods. Diagn. Microbiol. Infect. Dis. (2002) 43:13-17.
-
(2002)
Diagn. Microbiol. Infect. Dis.
, vol.43
, pp. 13-17
-
-
Roling, E.E.1
Klepser, M.E.2
Wasson, A.3
Lewis, R.E.4
Ernst, E.J.5
Pfaller, M.A.6
-
52
-
-
0032824392
-
Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits
-
PETRAITIENE R, PETRAITIS V, GROLL AH et al.: Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob. Agents Chemother. (1999) 43:2148-2155.
-
(1999)
Antimicrob. Agents Chemother.
, vol.43
, pp. 2148-2155
-
-
Petraitiene, R.1
Petraitis, V.2
Groll, A.H.3
-
53
-
-
0031783659
-
Antifungal efficacy, safety, and single dose plasma pharmacokinetics of LY3033666, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits
-
PETRAITIS V, PETRAITIENE R, GROLL A et al.: Antifungal efficacy, safety, and single dose plasma pharmacokinetics of LY3033666, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. (1998) 42:2898-2905.
-
(1998)
Antimicrob. Agents Chemother.
, vol.42
, pp. 2898-2905
-
-
Petraitis, V.1
Petraitiene, R.2
Groll, A.3
-
54
-
-
0002916585
-
LY303366 activity in a murine systemic candidiasis model
-
Washington DC, USA Abstract 365
-
ZECKNER D, BUTLER T, BOYLAN CJ, BOYLL B, LIN Y, RAAB P: LY303366 activity in a murine systemic candidiasis model. Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (1993) Abstract 365.
-
(1993)
Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Zeckner, D.1
Butler, T.2
Boylan, C.J.3
Boyll, B.4
Lin, Y.5
Raab, P.6
-
56
-
-
0037378033
-
In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis
-
ANDES D: In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother. (2003) 47:1179-1186.
-
(2003)
Antimicrob. Agents Chemother.
, vol.47
, pp. 1179-1186
-
-
Andes, D.1
-
57
-
-
0036093584
-
Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits
-
PETRAITIS V, PETRAITIENE R, GROLL AH et al.: Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. (2002) 46:1857-1867.
-
(2002)
Antimicrob. Agents Chemother.
, vol.46
, pp. 1857-1867
-
-
Petraitis, V.1
Petraitiene, R.2
Groll, A.H.3
-
58
-
-
0034016866
-
Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model
-
CHANDRASEKAR PH, CUTRIGHT J, MANAVATHU E: Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. J. Antimicrob. Chemother. (2000) 45:673-676.
-
(2000)
J. Antimicrob. Chemother.
, vol.45
, pp. 673-676
-
-
Chandrasekar, P.H.1
Cutright, J.2
Manavathu, E.3
-
60
-
-
0035118426
-
Antifungal activity and pharmacokinetics of posaconazole (SCH56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: Correlation with glactomannan antigenemia
-
PETRAITIENE R, PETRAITIS V, GROLL AH et al.: Antifungal activity and pharmacokinetics of posaconazole (SCH56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with glactomannan antigenemia. Antimicrob. Agents Chemother. (2001) 45:857-869.
-
(2001)
Antimicrob. Agents Chemother.
, vol.45
, pp. 857-869
-
-
Petraitiene, R.1
Petraitis, V.2
Groll, A.H.3
-
61
-
-
0028283764
-
Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1, 3)-β-D-glucan synthase
-
KURTZ MB, HEATH IB, MARRINON J, DRIEKORN S, ONISHI J, DOUGLAS C: Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1, 3)-β-D-glucan synthase. Antimicrob. Agents Chemother. (1994) 38:1480-1489.
-
(1994)
Antimicrob. Agents Chemother.
, vol.38
, pp. 1480-1489
-
-
Kurtz, M.B.1
Heath, I.B.2
Marrinon, J.3
Driekorn, S.4
Onishi, J.5
Douglas, C.6
-
62
-
-
0031691874
-
In vitro activity of echinocandin antifungal agent LY303366 in comparison with itraconazole and amphotericin B against Aspergillus spp
-
OAKLEY KL, MOORE CB, DENNING DW: In vitro activity of echinocandin antifungal agent LY303366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob. Agents Chemother. (1998) 42:2726-2730.
-
(1998)
Antimicrob. Agents Chemother.
, vol.42
, pp. 2726-2730
-
-
Oakley, K.L.1
Moore, C.B.2
Denning, D.W.3
-
63
-
-
0036720290
-
The antifungal echinocandin caspofungin acetate kills growing cells of aspergillus fumigatus in vitro
-
BOWMAN JC, FUCKS PS, KURTZ MB et al.: The antifungal echinocandin caspofungin acetate kills growing cells of aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. (2002) 46:3001-3012.
-
(2002)
Antimicrob. Agents Chemother.
, vol.46
, pp. 3001-3012
-
-
Bowman, J.C.1
Fucks, P.S.2
Kurtz, M.B.3
-
64
-
-
0034102140
-
Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans
-
ERNST EJ, KLEPSER ME, PFALLER MA: Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother. (2000) 44:1108-1111.
-
(2000)
Antimicrob. Agents Chemother.
, vol.44
, pp. 1108-1111
-
-
Ernst, E.J.1
Klepser, M.E.2
Pfaller, M.A.3
-
65
-
-
10744224705
-
Comparative antifungal susceptibility survey of 2,000 bloodstream isolates of Candida spp. from the United States
-
OSTROSKY-ZEICHNER L, REX JH, PAPPAS PG et al.: Comparative antifungal susceptibility survey of 2,000 bloodstream isolates of Candida spp. from the United States. Antimicrob. Agents Chemother. (2003) 47:3149-3154.
-
(2003)
Antimicrob. Agents Chemother.
, vol.47
, pp. 3149-3154
-
-
Ostrosky-Zeichner, L.1
Rex, J.H.2
Pappas, P.G.3
-
66
-
-
0030896916
-
In vitro susceptibilities of clinical yeast isolates to a new echinocandin deriative, LY303366, and other antifungal agents
-
PFALLER MA, MESSER SA, COFFMAN S: In vitro susceptibilities of clinical yeast isolates to a new echinocandin deriative, LY303366, and other antifungal agents. Antimicrob. Agents Chemother. (1997) 41:763-766.
-
(1997)
Antimicrob. Agents Chemother.
, vol.41
, pp. 763-766
-
-
Pfaller, M.A.1
Messer, S.A.2
Coffman, S.3
-
67
-
-
0344330764
-
Activity of an investigational echinocandin, LY303366, against fluconazole susceptible and resistant Canaida albicans in a multiple dose in vitro pharmacodynamic model
-
Toronto, Canada Abstract F72
-
ZELENITSKY S, KARLOWSKY J, HOBAN D et al.: Activity of an investigational echinocandin, LY303366, against fluconazole susceptible and resistant Canaida albicans in a multiple dose in vitro pharmacodynamic model. Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F72.
-
(1997)
Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Zelenitsky, S.1
Karlowsky, J.2
Hoban, D.3
-
68
-
-
0031713717
-
Susceptibilities of candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY303366 and other agents
-
ZHAENL GG, KARLOWSKY JA, ZELENITSKY S, TURIK MA, HOBAN DJ: Susceptibilities of candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY303366 and other agents. Antimicrob. Agents Chemother. (1998) 42:2446-2448.
-
(1998)
Antimicrob. Agents Chemother.
, vol.42
, pp. 2446-2448
-
-
Zhaenl, G.G.1
Karlowsky, J.A.2
Zelenitsky, S.3
Turik, M.A.4
Hoban, D.J.5
-
69
-
-
0038338453
-
Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Apergillus fumigatus
-
BARTIZAL K, ODDS FC: Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Apergillus fumigatus. Antimicrob. Agents Chemother. (2003) 47:2100-2107.
-
(2003)
Antimicrob. Agents Chemother.
, vol.47
, pp. 2100-2107
-
-
Bartizal, K.1
Odds, F.C.2
-
71
-
-
3142776290
-
Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by using an international collection of more than 3000 clinical isolates
-
PFALLER MA, MESSER SA, BOYKEN L et al.: Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by using an international collection of more than 3000 clinical isolates. J. Clin. Microbiol. (2004) 42:3117-3119.
-
(2004)
J. Clin. Microbiol.
, vol.42
, pp. 3117-3119
-
-
Pfaller, M.A.1
Messer, S.A.2
Boyken, L.3
-
72
-
-
0034758558
-
Antifungal susceptibility testing: Practical aspects and current challenges
-
REX JH, PFALLER MA, WALSH TJ et al.: Antifungal susceptibility testing: practical aspects and current challenges. Clin. Microbiol. Rev. (2001) 14:643-658.
-
(2001)
Clin. Microbiol. Rev.
, vol.14
, pp. 643-658
-
-
Rex, J.H.1
Pfaller, M.A.2
Walsh, T.J.3
-
73
-
-
4544276514
-
Susceptibility testing with caspofungin against Candida and Aspergillus species: An interlaboratory comparison
-
(In Press)
-
ODDS FC, MOTYL M, ANDRADE R et al.: Susceptibility testing with caspofungin against Candida and Aspergillus species: an interlaboratory comparison. Antimicrob. Agents Chemother. (2004) (In Press).
-
(2004)
Antimicrob. Agents Chemother.
-
-
Odds, F.C.1
Motyl, M.2
Andrade, R.3
-
74
-
-
0037667327
-
-
NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS: (2nd edition). National Committee For Clinical laboratory Standards Wayne, PA, USA M27-A2
-
NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS: Rtference method for broth dilution antifungal susceptibility testing of yeasts. approved standard (2nd edition). National Committee For Clinical laboratory Standards, Wayne, PA, USA (2002) M27-A2.
-
(2002)
Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard
-
-
-
75
-
-
0037417046
-
In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of candida spp., including 157 fluconazole-resistant isolates
-
PFALLER MA, DIEKEMA DJ, MESSER SA, HOLLIS RJ, JONES RN: In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of candida spp., including 157 fluconazole-resistant isolates. Antimicrob. Agents Chemother. (2003) 47:1068-1071.
-
(2003)
Antimicrob. Agents Chemother.
, vol.47
, pp. 1068-1071
-
-
Pfaller, M.A.1
Diekema, D.J.2
Messer, S.A.3
Hollis, R.J.4
Jones, R.N.5
-
76
-
-
4544322865
-
Comparison of the in vitro activity of anidulafungin with amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole against a panel of 780 yeasts obtained from five European centres
-
JOHNSON EM, GOLDSTEIN BP, DAVEY KG, FRASER MA: Comparison of the in vitro activity of anidulafungin with amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole against a panel of 780 yeasts obtained from five European centres. Clin. Microbiol. Infect. (2004) 10(Suppl. 13):113.
-
(2004)
Clin. Microbiol. Infect.
, vol.10
, Issue.SUPPL. 13
, pp. 113
-
-
Johnson, E.M.1
Goldstein, B.P.2
Davey, K.G.3
Fraser, M.A.4
-
78
-
-
1642363501
-
Infections due to emerging and uncommon medically important fungal pathogens
-
WALSH TJ, GROLL A, HIEMENZ J, FLEMING R, ROILIDES E, ANAISSIE E: Infections due to emerging and uncommon medically important fungal pathogens. Clin. Microbiol. Infect. Dis., (2004) 10(Suppl. 1):48-66.
-
(2004)
Clin. Microbiol. Infect. Dis.
, vol.10
, Issue.SUPPL. 1
, pp. 48-66
-
-
Walsh, T.J.1
Groll, A.2
Hiemenz, J.3
Fleming, R.4
Roilides, E.5
Anaissie, E.6
-
79
-
-
0001368075
-
Echinocandin antifungal agents
-
(2nd edition). Strohl WR (Ed.), Marcel Dekker, Inc., New York, USA
-
TURNER WW, CURRENT WL: Echinocandin antifungal agents. In: Biotechnology of Industrial Antibiotics (2nd edition). Strohl WR (Ed.), Marcel Dekker, Inc., New York, USA (1997):315-334.
-
(1997)
Biotechnology of Industrial Antibiotics
, pp. 315-334
-
-
Turner, W.W.1
Current, W.L.2
-
80
-
-
0035139521
-
Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis
-
PETRAITIS V, PETRAITIENE R, GROLL AH et al.: Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. (2001) 45:471-479.
-
(2001)
Antimicrob. Agents Chemother.
, vol.45
, pp. 471-479
-
-
Petraitis, V.1
Petraitiene, R.2
Groll, A.H.3
-
81
-
-
0034425534
-
Efficacacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis
-
ROBERTS J, SCHOCK K, MARINO S, ANDRIOLE VT: Efficacacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob. Agents Chemother. (2000) 44:3381-3388.
-
(2000)
Antimicrob. Agents Chemother.
, vol.44
, pp. 3381-3388
-
-
Roberts, J.1
Schock, K.2
Marino, S.3
Andriole, V.T.4
-
83
-
-
0242437957
-
Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study
-
ANAISSIE EJ, VARTIVARIAN SE, ABI-SAID O et al.: Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am. J. Med. (1996) 101:170-176.
-
(1996)
Am. J. Med.
, vol.101
, pp. 170-176
-
-
Anaissie, E.J.1
Vartivarian, S.E.2
Abi-Said, O.3
-
84
-
-
0028046352
-
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
-
REX JH, BENNETT JE, SUGAR AM et al.: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. (1994) 331:1325-1330.
-
(1994)
N. Engl. J. Med.
, vol.331
, pp. 1325-1330
-
-
Rex, J.H.1
Bennett, J.E.2
Sugar, A.M.3
-
85
-
-
0037508540
-
A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects
-
REX JH, PAPPAS PG, KARCHMER AW et al.: A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. Clin. Infect. Dis. (2003) 36:1221-1228.
-
(2003)
Clin. Infect. Dis.
, vol.36
, pp. 1221-1228
-
-
Rex, J.H.1
Pappas, P.G.2
Karchmer, A.W.3
|